FAKTOR-OPTIONSSCHEIN - MODERNA | Delayed Börse Stuttgart 09:03:08 2024-07-04 EDT | ||
| 0.173 EUR | +2.37% |
|
| Current month | -8.15% | ||
| 1 month | -55.53% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-04 | 0.173 | +2.37% |
| 24-07-03 | 0.169 | -3.98% |
| 24-07-02 | 0.176 | +2.33% |
| 24-07-01 | 0.172 | -6.52% |
| 24-06-28 | 0.184 | -7.54% |
Delayed Quote Börse Stuttgart
Last update July 04, 2024 at 09:03 am
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | Morgan Stanley |
| WKN | MC9A4X |
| ISIN | DE000MC9A4X0 |
| Date issued | 2020-05-04 |
| Strike | 77.32 $ |
| Maturity | Unlimited |
| Parity | 210.39 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 739.2 € |
|---|---|
| Lowest since issue | 0.064 € |
| Spread | 0.003 € |
| Spread % | 1.70% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
116
USD
Average target price
145.9
USD
Spread / Average Target
+25.79%
- Stock Market
- Certificates
- Certificat
